COX-2 expression does not correlate with microvessel density in breast cancer

Pathobiology

Volumn 76, Issue 1, 2009, Pages 39-44

  Thorat, Mangesh A ^a   Mehrotra, Sanjana ^a   Morimiya, Akira ^a   Badve, Sunil ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Breast cancer; Cyclooxygenase; Immunohistochemistry; Microvessel density

Indexed keywords

CD31 ANTIGEN; CYCLOOXYGENASE 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MALE; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 59649118087     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178154     Document Type: Article

References (35)

1. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-884.
2. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
3. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, et al: Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000;91:886-892.
4. Leris C, Mokbel K: The prevention of breast cancer: an overview. Curr Med Res Opin 2001;16:252-257.
5. Harris RE, Kasbari S, Farrar WB: Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999;6:71-73.
6. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-993.
7. Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-1250.
8. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-12872.
9. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-2696.
10. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
11. Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-2103.
12. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
13. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635.
14. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-5742.
15. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM: Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 1998;39:581-591.
16. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429-434.
17. Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M: Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003;9:2651-2656.
18. Beebe K: Glycerin antigen retrieval. Microsc Today 1999;30:30-31.
19. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, et al: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-2987.
20. Tynninen O, Sjostrom J, von Boguslawski K, Bengtsson NO, Heikkila R, Malmstrom P, et al: Tumour microvessel density as predictor of chemotherapy response in breast cancer patients. Br J Cancer 2002;86:1905-1908.
21. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
22. Rubio L, Burgos JS, Morera C, Vera-Sempere FJ: Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients. Pathol Oncol Res 2000;6:210-216.
23. Chow LWC, Loo WTY, Wai CCY, Lui ELH, Zhu L, Toi M: Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-fluorouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients. Biomed Pharmacother 2005;59(suppl 2):S298-S301.
24. Kelly LM, Hill ADK, Kennedy S, Connolly EM, Ramanath R, Teh S, et al: Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 2003;29:707-710.
25. Park K, Han S, Shin E, Kim HJ, Kim JY: Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol 2006;32:1093-1096.
26. Zerkowski M, Camp R, Burtness B, Rimm D, Chung G: Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest 2007;25:19-26.
27. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-1681.
28. Uzzan B, Nicolas P, Cucherat M, Perret GY: Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941-2955.
29. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C: The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 2000;6:139-146.
30. Vincent-Salomon A, Carton M, Zafrani B, Fréneaux P, Nicolas A, Massemin B, et al: Long term outcome of small size invasive breast carcinomas independent from angiogenesis in a series of 685 cases. Cancer 2001;92:249-256.
31. Mayers MM, Seshadri R, Raymond W, McCaul K, Horsfall DJ: Tumor microvascularity has no independent prognostic significance for breast cancer. Pathology 1998;30:105-110.
32. Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, Budman DR, et al: Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. J Clin Oncol 2002;20:732-742.
33. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
34. Basu G, Liang W, Stephan D, Wegener L, Conley C, Pockaj B, et al: A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res 2006;8:R69.
35. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, et al: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-770.